

In re application of  
Gregory M. Fahy  
Application No.: 10/066,285  
Page 2 of 9

Atty. Dkt. No. 074066-0115

**Amendment to the Claims/Listing of Claims**

Please amend claims 1, 5 and 6, and add claim 69 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A solution for the liquid state hypothermic preservation of cells, tissues, and organs, said solution comprising a combination of polyglycerol and lactose, wherein the polyglycerol concentration falls in the range of 10 mOsm to 250 mOsm, and wherein the lactose concentration falls in the range of 11 mM to 250 mM~~having a total osmotic concentration in the range of 20 milliosmolal to 250 milliosmolal .~~
2. (Previously presented) The solution of claim 1 wherein the lactose comprises alpha-lactose.
3. (Previously presented) The solution of claim 1 wherein the polyglycerol comprises from 2 to 200 monomer units.
4. (Previously presented) The solution of claim 1 wherein the polyglycerol is decaglycerol or hexaglycerol.
5. (Currently amended) The solution of claim 1 wherein the lactose concentration falls in the range of ~~[[11]]~~ 20 mM to ~~[[250]]~~ 150 mM.
6. (Currently amended) The solution of claim 1 wherein the polyglycerol concentration falls in the range of ~~[[10]]~~ 20 mOsm to ~~[[250]]~~ 200 mOsm.

In re application of  
Gregory M. Fahy  
Application No.: 10/066,285  
Page 3 of 9

Atty. Dkt. No. 074066-0115

7-35. (Cancelled)

36. (Previously presented) The solution of claim 1 further comprising glutathione.

37. (Withdrawn) The solution of claim 1, further comprising chondroitin sulfate.

38. (Withdrawn) The solution of claim 37 wherein the chondroitin sulfate is chondroitin sulfate A.

39. (Withdrawn) The solution of claim 37, wherein the concentration of chondroitin sulfate falls in the range of 0.01% w/v to 1% w/v.

40. (Withdrawn) The solution of claim 1, further comprising chlorpromazine.

41. (Withdrawn) The solution of claim 40, wherein the concentration of chlorpromazine is about 1-50 micrograms/ml.

42. (Withdrawn) The solution of claim 41, wherein the concentration of chlorpromazine is about 2-10 micrograms/ml.

43. (Withdrawn) The solution of claim 1, further comprising citrate.

44. (Withdrawn) The solution of claim 1, further comprising calcium.

45. (Withdrawn) The solution of claim 1, further comprising magnesium.

In re application of  
Gregory M. Fahy  
Application No.: 10/066,285  
Page 4 of 9

Atty. Dkt. No. 074066-0115

46. (Withdrawn) The solution of claim 1, further comprising adenine.
47. (Withdrawn) The solution of claim 1, further comprising glucose.
48. (Withdrawn) The solution of claim 1, further comprising acetate.
49. (Withdrawn) The solution of claim 1, further comprising phosphate buffer.
50. (Previously presented) The solution of claim 1, wherein the solution has an osmolality of less than about 350 mOsm.
51. (Withdrawn) The solution of claim 1, further comprising citrate and glucose, wherein the sum of the osmotic contributions of polyglycerol, lactose, citrate and glucose to the solution is 20-250 mOsm (milliosmolal).
52. (Withdrawn) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:  
contacting the cells, tissues, or organs with a solution of claim 1.
53. (Withdrawn) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:  
contacting the cells, tissues, or organs with a solution comprising polyglycerol in an amount effective to preclude or to reverse cell swelling.
54. (Withdrawn) The method of claim 53 wherein the contacting is via intravenous or intra-arterial administration.

In re application of  
Gregory M. Fahy  
Application No.: 10/066,285  
Page 5 of 9

Atty. Dkt. No. 074066-0115

55. (Withdrawn) The method of claim 53 wherein the contacting is in vivo via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.

56. (Withdrawn) The method of claim 53 wherein the contacting is in vitro via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.

57. (Withdrawn) The method of claim 53 wherein the contacting is via the immersion of or bathing of affected cells, tissues, or organs.

58. (Cancelled)

59. (Withdrawn) The method of claim 53 wherein the polyglycerol comprises from 2 to 200 monomer units.

60. (Withdrawn) The method of claim 53 wherein the polyglycerol is tetraglycerol, hexaglycerol, or decaglycerol.

61. (Withdrawn) The method of claim 53 wherein the concentration of polyglycerol in contact with the cell, tissue, or organ is from about 20 mOsm to 1,500 mOsm.

62. (Withdrawn) The method of claim 53 wherein the effective amount is an isotonic solution.

63. (Withdrawn) The method of claim 53 wherein the effective amount is a hypertonic solution.

In re application of  
Gregory M. Fahy  
Application No.: 10/066,285  
Page 6 of 9

Atty. Dkt. No. 074066-0115

64. (Withdrawn) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

contacting the cells, tissues, or organs with a solution comprising lactose in an amount effective to preclude or to reverse cell swelling.

65. (Withdrawn) The method of claim 64 wherein the lactose comprises alpha lactose.

66. (Withdrawn) The method of claim 64 wherein the lactose concentration falls in the range of about 11 mM to about 250 mM.

67-68. (Cancelled)

69. (New) The solution of claim 1 wherein the osmotic concentration of the combination of polyglycerol and lactose falls in the range of 50 milliosmolal to 250 milliosmolal.